Catalyst Pharma Q3 rev $148.4M (+17% YoY); raises FY25 revenue guidance to $565-$585M

CATALYST PHARMACEUTICALS, INC.

2025-Q3 EPS reported $1.27 vs consensus $0.34 ▲ beat (+275.1%)

GAAP net income $52.8M ($0.42 diluted EPS); non-GAAP net income $86.1M ($0.68 diluted EPS).
FIRDAPSE net revenue $92.2M (+16.2% YoY); AGAMREE net revenue $32.4M (+115.2% YoY).
FYCOMPA net revenue $23.8M (-25.8% YoY) as first generic tablet entered market in Q2 2025.
Cash and equivalents $689.9M as of Sep 30, 2025; $200M share repurchase program announced.
Full-year AGAMREE guidance raised to $105-$115M; FYCOMPA guidance raised to $100-$110M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.